Dr. Michael Ye is a Partner in the firm’s Intellectual Property practice. Dr. Ye has extensive experience in patent prosecution, opinion work, due diligence and licensing, as well as trademark prosecution and licensing, and copyright. Dr. Ye has handled drafting and prosecuting patent applications globally, inter partes review and post grant proceedings, product clearance searches, product evaluations, inventorship analysis, non-disclosure agreements and licensing agreements. He has substantial experience across the breadth of life sciences, in particular in biotechnology, chemistry/organic chemistry, bioinformatics, cosmetics, pharmaceuticals, medical devices, agriculture and artificial intelligence.
Dr. Ye is named among the worlds leading patent practitioners in IAM Patent 1000, the top worldwide guide to leading patent professionals and firms. Dr. Ye has extensive experience in inbound and outbound negotiations and business transactions in China. His cultural sensitivities, linguistics capabilities and technical expertise enhance his successful prosecution, opinion, due diligence and licensing work. Dr. Ye focuses on securing commercially valuable claims that align with clients business strategies, as well as identifying and developing licensing opportunities globally. He provides advice and strategic overview regarding management and development of patent portfolios, including advice on licensing and trademarks.
Prior to legal practice, Dr. Ye was an assistant professor of biochemistry and molecular biology at George Washington University and Children’s National Medical Center from 1997 to 2002. His research experience included areas such as gene and cell therapy, transgenics, molecular immunology and vaccine development.
Dr. Ye has authored or co-authored 28 peer-reviewed scientific articles, including an article in the prestigious journal Science. He was the recipient of the National Institutes of Health’s National Research Service Award and the recipient of the Award for Scientific and Academic Achievement from the Children’s Medical Center.
Awards and Recognition
- IAM Patent 1000: Patent Prosecution, 2016, 2017, 2020, 2021
- Chambers USA, Intellectual Property: Patent Prosecution, 2021
- Commercialization strategies for early stage drug-related startups – Co-Auther, Westlaw Journal (March 25, 2020)
- Coronavirus Drug Shows Global Hurdles to Patent Protection, Co-Author, Law360, February 2020
- New USPTO Guidance May Help Diagnostics Patents, Co-Author, Law360, April, 2019
- New Proposed Rules Regarding Government Rights in Federally Funded Research: Bayh-Dole Act, Co-Author, The National Law Review, February, 2017
- Winning The Battle But Losing The War? – New Considerations For File Wrapper Estoppel – Co-Auther IP Law360 (December 22, 2014)
- The Myriad Decision in the U.S. Supreme Court, Co-Author, The National Law Review, July, 2012
- Is an Isolated DNA Patentable?, Co-Author, The National Law Review, October, 2011
Scientific Publications (Selected from 28 Peer-Reviewed Publications)
- Ye, J. McCarrick, L. Jewett and B.B. Knowles, “Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice” Proc. Natl. Acad. Sci. USA 91, 3916-3920, 1994.
- F. Engelhardt, X. Ye, B. Doranz and J.M. Wilson, “Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver” Proc. Natl. Acad. Sci. USA 91, 6196-6200, 1994.
- Ye, M.B. Robinson, M.L. Batshaw, E.E. Furth, I. Smith and J.M. Wilson, “Prolonged metabolic correction in adult ornithine transcarbamylase deficiency mice with adenoviral vectors” J. Biol. Chem. 271, 3639-3646, 1996.
- Ye, G. Gao, Carol Pabin, S. E. Raper and J. M. Wilson, “Evaluating the potential of germline transmission after intravenous administration of recombinant adenovirus in the C3H mouse” Hum. Gene Ther. 9, 2135-2142, 1998.
- Ye, V.M. Rivera, P. Zoltick, F. Cerasoli, M.A. Schnell, G. Gao, J.V. Hughes, M. Gilman and J.M. Wilson, “Regulated delivery of therapeutic proteins following in vivo somatic cell gene transfer” Science, 283, 88-91, 1999.
- M. Rivera, X. Ye, N.L. Courage, F. Cerasoli Jr., J.M. Wilson and M. Gilman, “Long-term regulated gene expression in mice following intramuscular gene transfer” Proc. Natl. Acad. Sci. USA, 96:8657-8662, 1999.
- Ye, M. Jerebtsova and P.E. Ray, “Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine and kidney” Hum Gene Ther, 11:621-628, 2000.
- Ye, B. Whiteman, M. Jerebtsova and M.L. Batshaw, “Correction of argininosuccinate synthetase (AS) deficiency in a murine model of citrullinemia with recombinant adenovirus carrying human AS cDNA” Gene Ther, 7:1777-1782, 2000.
- Ye, M.B. Robinson, C. Pabin, M.L. Batshaw and J.M. Wilson, “Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mice” Gene Ther, 7:1761-1767, 2000.
- Ye, X. Liu, Z. Li and P.E. Ray, “Efficient gene transfer to rat renal glomeruli with recombinant adenoviral vectors” Hum Gene Ther, 12:141-148, 2001.
- Ye, K.P. Zimmer, R. Brown, C. Pabin, M.L. Batshaw, J.M. Wilson and M.B. Robinson, “Differences in the human and mouse amino terminal leader peptides of ornithine transcarbamylase affect mitochondrial import and efficacy of adenoviral vectors” Hum Gene Ther. 12: 1035-1046, 2001.
- Ye, M. Jerebtsova, X. Liu, Z. Li and P.E. Ray, “Adenovirus-mediated gene transfer to renal glomeruli in rodents” Kidney International 61 Suppl 1:16-23, 2002.